In focus · trending topic

Through 505(b)(2) Accelerated

1 stories · following the connections

BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process

By Nasdaq OMXMar 26, 2018, 11:22 PM UTC